News | March 24, 2026
Japan okays new long-acting eye drug
It promises fewer injections for vision loss patients
It promises fewer injections for vision loss patients
This follows a $6 million expansion in Rosenberg in 2025 and signals a major push to boost commercial capacity, expand R&D capabilities, and meet rising demand for US-based drug product manufacturing
These approvals represent a defining moment for people living with classical Hodgkin Lymphoma
RSM01, a preventive treatment targeting respiratory syncytial virus (RSV), was licensed earlier this month from the Gates Medical Research Institute
COVIRIX Medical says its broad-spectrum antiviral portfolio has already shown positive virology results against key pandemic threats
The new entity will operate with separate resources, funding, and operations, while BioNTech will contribute related rights and mRNA technologies to support its ambitious mission
The move comes as China rapidly expands its capabilities in the pharmaceutical sector, particularly in licensing and drug development
The expansion builds on Veristat’s work helping Chinese pharmaceutical firms such as Hansoh Pharma and CStone Pharmaceuticals
Huwel’s diagnostic solutions leverage open RT-PCR system
The FDA decision was based on results from the pivotal POETYK PsA-1 and POETYK PsA-2 Phase 3 trials
Subscribe To Our Newsletter & Stay Updated
